
Biogen Inc (NASDAQ:BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval.
An analyst at RBC Capital Markets has now turned bullish on the stock after remaining on the sidelines for too long.